The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of metastatic urothelial carcinoma pts discontinuing enfortumab vedotin.
 
Jasmeet Kaur
No Relationships to Disclose
 
Nagendra Dhanikonda
No Relationships to Disclose
 
Karthik Devarajan
Stock and Other Ownership Interests - AstraZeneca Canada; Bristol-Myers Squibb Foundation/Janssen
 
Fern Anari
No Relationships to Disclose
 
Matthew Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - Adicet Bio; AVEO; Exelixis; Merck
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst)
 
Daniel Geynisman
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); CG Oncology (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)